Table of Contents

company-logo

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics Dividend Announcement

• Capricor Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Capricor Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Capricor Therapeutics Dividend History

Capricor Therapeutics Dividend Yield

Capricor Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Capricor Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Capricor Therapeutics Financial Ratios

P/E ratio-22.26
PEG ratio2.16
P/B ratio54.09
ROE-220.26%
Payout ratio0.00%
Current ratio1.37
Quick ratio1.37
Cash Ratio0.48

Capricor Therapeutics Dividend FAQ

Does Capricor Therapeutics stock pay dividends?
Capricor Therapeutics does not currently pay dividends to its shareholders.
Has Capricor Therapeutics ever paid a dividend?
No, Capricor Therapeutics has no a history of paying dividends to its shareholders. Capricor Therapeutics is not known for its dividend payments.
Why doesn't Capricor Therapeutics pay dividends?
There are several potential reasons why Capricor Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Capricor Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Capricor Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Capricor Therapeutics a dividend aristocrat?
Capricor Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Capricor Therapeutics a dividend king?
Capricor Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Capricor Therapeutics a dividend stock?
No, Capricor Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Capricor Therapeutics stocks?
To buy Capricor Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Capricor Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.